{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:54:01Z","timestamp":1791082441976,"version":"4.1.0"},"reference-count":132,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012131","name":"Department of Science & Technology of Liaoning Province","doi-asserted-by":"publisher","award":["2024JH2\/102600330"],"award-info":[{"award-number":["2024JH2\/102600330"]}],"id":[{"id":"10.13039\/501100012131","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.nbd.2026.107603","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:16:14Z","timestamp":1788970574000},"page":"107603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["MicroRNAs in polyglutamine diseases: Mechanistic insights, circulating biomarkers, and emerging microRNA-based therapeutic strategies"],"prefix":"10.1016","volume":"229","author":[{"given":"Yang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyan","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.nbd.2026.107603_bb0005","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1021\/acs.biochem.6b00936","article-title":"Proteins containing expanded polyglutamine tracts and neurodegenerative disease","volume":"56","author":"Adegbuyiro","year":"2017","journal-title":"Biochemistry"},{"key":"10.1016\/j.nbd.2026.107603_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116899","article-title":"MicroRNA (miRNA) as a biomarker for diagnosis, prognosis, and therapeutics molecules in neurodegenerative disease","volume":"177","author":"Alkhazaali-Ali","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.nbd.2026.107603_bb0015","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.mito.2023.05.007","article-title":"Mitochondrial dysfunction and oxidative stress in Alzheimer\u2019s disease, and Parkinson\u2019s disease, Huntington\u2019s disease and amyotrophic lateral sclerosis -an updated review","volume":"71","author":"Alqahtani","year":"2023","journal-title":"Mitochondrion"},{"issue":"4","key":"10.1016\/j.nbd.2026.107603_bb0020","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1007\/s13311-019-00790-9","article-title":"Molecular mechanisms and therapeutics for SBMA\/Kennedy\u2019s disease","volume":"16","author":"Arnold","year":"2019","journal-title":"Neurotherapeutics"},{"issue":"2","key":"10.1016\/j.nbd.2026.107603_bb0025","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.bbrc.2017.05.040","article-title":"MicroRNA-27a reduces mutant huntingtin aggregation in an in vitro model of Huntington\u2019s disease","volume":"488","author":"Ban","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.nbd.2026.107603_bb0030","doi-asserted-by":"crossref","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","article-title":"Huntington disease","volume":"1","author":"Bates","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.nbd.2026.107603_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2019.101732","article-title":"Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders","volume":"185","author":"van den Berg","year":"2020","journal-title":"Prog. Neurobiol."},{"issue":"9","key":"10.1016\/j.nbd.2026.107603_bb0040","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1007\/s12035-019-1480-y","article-title":"Wide profiling of circulating microRNAs in spinocerebellar ataxia type 7","volume":"56","author":"Borgonio-Cuadra","year":"2019","journal-title":"Mol. Neurobiol."},{"issue":"2","key":"10.1016\/j.nbd.2026.107603_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/ijms27020683","article-title":"Integrated plasma and glial cell evidence indicates a functional role for hsa-miR-342-5p in spinocerebellar ataxia type 7 and its potential use as a biomarker","volume":"27","author":"Borgonio-Cuadra","year":"2026","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.nbd.2026.107603_bb0050","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0092-8674(03)00231-9","article-title":"Bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila","volume":"113","author":"Brennecke","year":"2003","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.nbd.2026.107603_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0030085","article-title":"Principles of microRNA-target recognition","volume":"3","author":"Brennecke","year":"2005","journal-title":"PLoS Biol."},{"issue":"7","key":"10.1016\/j.nbd.2026.107603_bb0060","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/acn3.51370","article-title":"Spinocerebellar ataxia clinical trials: opportunities and challenges","volume":"8","author":"Brooker","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"4","key":"10.1016\/j.nbd.2026.107603_bb0065","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.ymthe.2017.01.021","article-title":"Unravelling endogenous microRNA system dysfunction as a new pathophysiological mechanism in Machado-Joseph disease","volume":"25","author":"Carmona","year":"2017","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.nbd.2026.107603_bb0070","first-page":"36","article-title":"Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease","volume":"48","author":"Caron","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.nbd.2026.107603_bb0075","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.omtm.2022.04.004","article-title":"Combined overexpression of ATXN1L and mutant ATXN1 knockdown by AAV rescue motor phenotypes and gene signatures in SCA1 mice","volume":"25","author":"Carrell","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"Pt 2","key":"10.1016\/j.nbd.2026.107603_bb0080","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.freeradbiomed.2023.10.407","article-title":"miR-196a provides antioxidative neuroprotection via USP15\/Nrf2 regulation in Huntington\u2019s disease","volume":"209","author":"Chan","year":"2023","journal-title":"Free Radic. Biol. Med."},{"issue":"16","key":"10.1016\/j.nbd.2026.107603_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168424","article-title":"MiR-302 attenuates mutant huntingtin-induced cytotoxicity through restoration of autophagy and insulin sensitivity","volume":"22","author":"Chang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.nbd.2026.107603_bb0090","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s13023-017-0742-x","article-title":"Down-regulation of miR-9* in the peripheral leukocytes of Huntington\u2019s disease patients","volume":"12","author":"Chang","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.nbd.2026.107603_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.mad.2020.111215","article-title":"SIRT1 and aging related signaling pathways","volume":"187","author":"Chen","year":"2020","journal-title":"Mech. Ageing Dev."},{"issue":"2","key":"10.1016\/j.nbd.2026.107603_bb0100","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/bib\/bbx130","article-title":"MicroRNAs and complex diseases: from experimental results to computational models","volume":"20","author":"Chen","year":"2019","journal-title":"Brief. Bioinform."},{"issue":"4","key":"10.1016\/j.nbd.2026.107603_bb0105","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.bbrc.2016.08.042","article-title":"Mitochondrial fragmentation in neuronal degeneration: toward an understanding of HD striatal susceptibility","volume":"483","author":"Cherubini","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.nbd.2026.107603_bb0110","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00018-020-03596-7","article-title":"Artificial miRNAs targeting CAG repeat expansion in ORFs cause rapid deadenylation and translation inhibition of mutant transcripts","volume":"78","author":"Ciesiolka","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.nbd.2026.107603_bb0115","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s13311-023-01357-5","article-title":"Contribution of glial cells to polyglutamine diseases: observations from patients and mouse models","volume":"20","author":"Cvetanovic","year":"2023","journal-title":"Neurotherapeutics"},{"issue":"2","key":"10.1016\/j.nbd.2026.107603_bb0120","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2174\/2211536604666150713105606","article-title":"Delayed cell cycle progression in STHdh(Q111)\/Hdh(Q111) cells, a cell model for Huntington\u2019s disease mediated by microRNA-19a, microRNA-146a and microRNA-432","volume":"4","author":"Das","year":"2015","journal-title":"Microrna"},{"key":"10.1016\/j.nbd.2026.107603_bb0125","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.phrs.2016.05.005","article-title":"Circulating microRNAs in Huntington\u2019s disease: emerging mediators in metabolic impairment","volume":"108","author":"D\u00edez-Planelles","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.nbd.2026.107603_bb0130","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3389\/fnmol.2019.00156","article-title":"The emerging role of microRNAs in polyglutamine diseases","volume":"12","author":"Dong","year":"2019","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.nbd.2026.107603_bb0135","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2021.705348","article-title":"MicroRNAs in Huntington\u2019s disease: diagnostic biomarkers or therapeutic agents?","volume":"15","author":"Dong","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.nbd.2026.107603_bb0140","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3389\/fendo.2018.00614","article-title":"High levels of SIRT1 expression as a protective mechanism against disease-related conditions","volume":"9","author":"Elibol","year":"2018","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"4","key":"10.1016\/j.nbd.2026.107603_bb0145","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3233\/JHD-229006","article-title":"Huntington\u2019s disease clinical trials corner: November 2022","volume":"11","author":"Estevez-Fraga","year":"2022","journal-title":"J. Huntingtons Dis."},{"issue":"10","key":"10.1016\/j.nbd.2026.107603_bb0150","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1080\/14712598.2020.1792880","article-title":"AAV5-miHTT gene therapy for Huntington disease: lowering both huntingtins","volume":"20","author":"Evers","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"issue":"3","key":"10.1016\/j.nbd.2026.107603_bb0155","first-page":"1513","article-title":"Ataxin-3 protein and RNA toxicity in spinocerebellar ataxia type 3: current insights and emerging therapeutic strategies","volume":"49","author":"Evers","year":"2014","journal-title":"Mol. Neurobiol."},{"issue":"9","key":"10.1016\/j.nbd.2026.107603_bb0160","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/j.ymthe.2018.06.021","article-title":"AAV5-miHTT gene therapy demonstrates broad distribution and strong human mutant huntingtin lowering in a Huntington\u2019s disease minipig model","volume":"26","author":"Evers","year":"2018","journal-title":"Mol. Ther."},{"issue":"8","key":"10.1016\/j.nbd.2026.107603_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201794","article-title":"Upregulation of miR-370 and miR-543 is associated with reduced expression of heat shock protein 40 in spinocerebellar ataxia type 3","volume":"13","author":"Evert","year":"2018","journal-title":"PloS One"},{"issue":"6","key":"10.1016\/j.nbd.2026.107603_bb0170","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.tibs.2018.03.002","article-title":"Conformation polymorphism of polyglutamine proteins","volume":"43","author":"Feng","year":"2018","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.nbd.2026.107603_bb0175","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.657973","article-title":"Circulating hsa-miR-323b-3p in Huntington\u2019s disease: a pilot study","volume":"12","author":"Ferraldeschi","year":"2021","journal-title":"Front. Neurol."},{"issue":"3","key":"10.1016\/j.nbd.2026.107603_bb0180","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/JHD-230578","article-title":"Sleep, circadian rhythms, and cognitive dysfunction in Huntington\u2019s disease","volume":"12","author":"Fitzgerald","year":"2023","journal-title":"J. Huntingtons Dis."},{"issue":"9","key":"10.1016\/j.nbd.2026.107603_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0137637","article-title":"The potential regulatory mechanisms of miR-196a in Huntington\u2019s disease through bioinformatic analyses","volume":"10","author":"Fu","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.nbd.2026.107603_bb0190","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.omtn.2018.01.007","article-title":"Supplemental treatment for Huntington\u2019s disease with miR-132 that is deficient in Huntington\u2019s disease brain","volume":"11","author":"Fukuoka","year":"2018","journal-title":"Mol. Ther. Nucl. Acids."},{"issue":"1","key":"10.1016\/j.nbd.2026.107603_bb0195","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s10020-023-00640-7","article-title":"MiR-34a-5p as molecular hub of pathomechanisms in Huntington\u2019s disease","volume":"29","author":"Hart","year":"2023","journal-title":"Mol. Med."},{"issue":"4","key":"10.1016\/j.nbd.2026.107603_bb0200","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.tins.2008.12.003","article-title":"Alterations of the microRNA network cause neurodegenerative disease","volume":"32","author":"H\u00e9bert","year":"2009","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.nbd.2026.107603_bb0205","doi-asserted-by":"crossref","DOI":"10.1038\/srep44849","article-title":"Huntington\u2019s disease blood and brain show a common gene expression pattern and share an immune signature with Alzheimer\u2019s disease","volume":"7","author":"Hensman Moss","year":"2017","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.nbd.2026.107603_bb0210","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.7150\/thno.18813","article-title":"miR-196a enhances neuronal morphology through suppressing RANBP10 to provide neuroprotection in Huntington\u2019s disease","volume":"7","author":"Her","year":"2017","journal-title":"Theranostics"},{"issue":"6","key":"10.1016\/j.nbd.2026.107603_bb0215","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbac397","article-title":"Updated review of advances in microRNAs and complex diseases: experimental results, databases, webservers and data fusion","volume":"23","author":"Huang","year":"2022","journal-title":"Brief. Bioinform."},{"issue":"6","key":"10.1016\/j.nbd.2026.107603_bb0220","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.3390\/cells9061345","article-title":"Mitochondrial microRNAs in aging and neurodegenerative diseases","volume":"9","author":"John","year":"2020","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.nbd.2026.107603_bb0225","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s12017-009-8063-4","article-title":"Gene dysregulation in Huntington\u2019s disease: REST, microRNAs and beyond","volume":"11","author":"Johnson","year":"2009","journal-title":"Neuromolecular Med."},{"issue":"3","key":"10.1016\/j.nbd.2026.107603_bb0230","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.nbd.2007.11.001","article-title":"A microRNA-based gene dysregulation pathway in Huntington\u2019s disease","volume":"29","author":"Johnson","year":"2008","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"10.1016\/j.nbd.2026.107603_bb0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054222","article-title":"MicroRNA-22 (miR-22) overexpression is neuroprotective via general anti-apoptotic effects and may also target specific Huntington\u2019s disease-related mechanisms","volume":"8","author":"Jovicic","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2026.107603_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2019.101664","article-title":"MicroRNA dysregulation in neurodegenerative diseases: a systematic review","volume":"182","author":"Ju\u017awik","year":"2019","journal-title":"Prog. Neurobiol."},{"issue":"2","key":"10.1016\/j.nbd.2026.107603_bb0245","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ng1094-148","article-title":"Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain","volume":"8","author":"Kaplitt","year":"1994","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.nbd.2026.107603_bb0250","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cell.2007.09.020","article-title":"The conserved microRNA miR-8 tunes atrophin levels to prevent neurodegeneration in Drosophila","volume":"131","author":"Karres","year":"2007","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.nbd.2026.107603_bb0255","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/mt.2013.279","article-title":"Broad therapeutic benefit after RNAi expression vector delivery to deep cerebellar nuclei: implications for spinocerebellar ataxia type 1 therapy","volume":"22","author":"Keiser","year":"2014","journal-title":"Mol. Ther."},{"issue":"11","key":"10.1016\/j.nbd.2026.107603_bb0260","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1038\/s41591-021-01522-3","article-title":"Toxicity after AAV delivery of RNAi expression constructs into nonhuman primate brain","volume":"27","author":"Keiser","year":"2021","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.nbd.2026.107603_bb0265","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3390\/biom13050788","article-title":"Therapeutic strategies for spinocerebellar ataxia type 1","volume":"13","author":"Kerkhof","year":"2023","journal-title":"Biomolecules"},{"issue":"16","key":"10.1016\/j.nbd.2026.107603_bb0270","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2322924121","article-title":"Posttranscriptional regulation of FAN1 by miR-124-3p at rs3512 underlies onset-delaying genetic modification in Huntington\u2019s disease","volume":"121","author":"Kim","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"23","key":"10.1016\/j.nbd.2026.107603_bb0275","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.3390\/ijms20236055","article-title":"Interplay between microRNAs and oxidative stress in neurodegenerative diseases","volume":"20","author":"Konovalova","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.nbd.2026.107603_bb0280","article-title":"Artificial miRNAs as therapeutic tools: challenges and opportunities","volume":"12","author":"Kotowska-Zimmer","year":"2021","journal-title":"Wiley Interdiscip. Rev.: RNA"},{"issue":"D1","key":"10.1016\/j.nbd.2026.107603_bb0285","doi-asserted-by":"crossref","first-page":"D155","DOI":"10.1093\/nar\/gky1141","article-title":"miRBase: from microRNA sequences to function","volume":"47","author":"Kozomara","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"9","key":"10.1016\/j.nbd.2026.107603_bb0290","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.jmb.2019.01.019","article-title":"The role of microRNAs in spinocerebellar ataxia type 3","volume":"431","author":"Krauss","year":"2019","journal-title":"J. Mol. Biol."},{"issue":"1","key":"10.1016\/j.nbd.2026.107603_bb0295","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2174\/2211536607666180821162403","article-title":"Upregulation of miR-25 and miR-181 family members correlates with reduced expression of ATXN3 in lymphocytes from SCA3 patients","volume":"8","author":"Krauss","year":"2019","journal-title":"Microrna"},{"issue":"9","key":"10.1016\/j.nbd.2026.107603_bb0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162788","article-title":"miR-196a ameliorates cytotoxicity and cellular phenotype in transgenic Huntington\u2019s disease monkey neural cells","volume":"11","author":"Kunkanjanawan","year":"2016","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.nbd.2026.107603_bb0305","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190550","article-title":"MicroRNA signatures of endogenous huntingtin CAG repeat expansion in mice","volume":"13","author":"Langfelder","year":"2018","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.nbd.2026.107603_bb0310","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0092-8674(93)90529-Y","article-title":"The C. Elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14","volume":"75","author":"Lee","year":"1993","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.nbd.2026.107603_bb0315","doi-asserted-by":"crossref","first-page":"45","DOI":"10.14802\/jmd.16054","article-title":"Exosome-based delivery of miR-124 in a Huntington\u2019s disease model","volume":"10","author":"Lee","year":"2017","journal-title":"J. Mov. Disord."},{"issue":"1","key":"10.1016\/j.nbd.2026.107603_bb0320","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41598-025-85612-z","article-title":"Integrated analysis of miRNAs and mRNAs in thousands of single cells","volume":"15","author":"Li","year":"2025","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.nbd.2026.107603_bb0325","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10549-018-4757-3","article-title":"Circulating microRNAs from the miR-106a-363 cluster on chromosome X as novel diagnostic biomarkers for breast cancer","volume":"170","author":"Li","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.nbd.2026.107603_bb0330","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/ene.14094","article-title":"The complex phenotype of spinocerebellar ataxia type 48 in eight unrelated Italian families","volume":"27","author":"Lieto","year":"2020","journal-title":"Eur. J. Neurol."},{"issue":"7386","key":"10.1016\/j.nbd.2026.107603_bb0335","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature10810","article-title":"The microRNA miR-34 modulates ageing and neurodegeneration in Drosophila","volume":"482","author":"Liu","year":"2012","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.nbd.2026.107603_bb0340","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s13311-019-00762-z","article-title":"Molecular mechanisms and therapeutics for SCA17","volume":"16","author":"Liu","year":"2019","journal-title":"Neurotherapeutics"},{"issue":"5","key":"10.1016\/j.nbd.2026.107603_bb0345","doi-asserted-by":"crossref","first-page":"786","DOI":"10.4103\/1673-5374.156978","article-title":"MicroRNA-124 slows down the progression of Huntington\u2019s disease by promoting neurogenesis in the striatum","volume":"10","author":"Liu","year":"2015","journal-title":"Neural Regen. Res."},{"issue":"11","key":"10.1016\/j.nbd.2026.107603_bb0350","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115673","article-title":"Dysregulation of muscle-specific microRNAs as common pathogenic feature associated with muscle atrophy in ALS, SMA and SBMA: evidence from animal models and human patients","volume":"22","author":"Malacarne","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.nbd.2026.107603_bb0355","doi-asserted-by":"crossref","first-page":"8502","DOI":"10.1007\/s12035-025-04750-7","article-title":"The role of MicroRNAs in neurodegeneration: insights from Huntington\u2019s disease","volume":"62","author":"Mansour","year":"2025","journal-title":"Mol Neurobiol."},{"key":"10.1016\/j.nbd.2026.107603_bb0360","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.omtm.2019.10.008","article-title":"Development of an AAV-based microRNA gene therapy to treat Machado-Joseph disease","volume":"15","author":"Martier","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"11","key":"10.1016\/j.nbd.2026.107603_bb0365","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.4103\/1673-5374.310673","article-title":"Altered microRNA expression in animal models of Huntington\u2019s disease and potential therapeutic strategies","volume":"16","author":"Martinez","year":"2021","journal-title":"Neural Regen. Res."},{"issue":"1","key":"10.1016\/j.nbd.2026.107603_bb0370","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ene.13413","article-title":"Huntington\u2019s disease: a clinical review","volume":"25","author":"McColgan","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.nbd.2026.107603_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104635","article-title":"Pathogenesis of SCA3 and implications for other polyglutamine diseases","volume":"134","author":"McLoughlin","year":"2020","journal-title":"Neurobiol. Dis."},{"issue":"8","key":"10.1016\/j.nbd.2026.107603_bb0380","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/nmeth.3014","article-title":"Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study","volume":"11","author":"Mestdagh","year":"2014","journal-title":"Nat. Methods"},{"issue":"7","key":"10.1016\/j.nbd.2026.107603_bb0385","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/nm.2791","article-title":"Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2","volume":"18","author":"Miyazaki","year":"2012","journal-title":"Nat. Med."},{"issue":"347","key":"10.1016\/j.nbd.2026.107603_bb0390","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf5660","article-title":"An miRNA-mediated therapy for SCA6 blocks IRES-driven translation of the CACNA1A second cistron","volume":"8","author":"Miyazaki","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.nbd.2026.107603_bb0395","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1101\/gad.225151.113","article-title":"Loss of Drosophila ataxin-7, a SAGA subunit, reduces H2B ubiquitination and leads to neural and retinal degeneration","volume":"28","author":"Mohan","year":"2014","journal-title":"Genes Dev."},{"issue":"2","key":"10.1016\/j.nbd.2026.107603_bb0400","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.nbd.2011.12.046","article-title":"MicroRNAs in Parkinson\u2019s disease","volume":"46","author":"Mouradian","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2026.107603_bb0405","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2024.1421680","article-title":"Beneficial effects of miR-132\/212 deficiency in the zQ175 mouse model of Huntington\u2019s disease","volume":"18","author":"Nateghi","year":"2024","journal-title":"Front. Neurosci."},{"issue":"9","key":"10.1016\/j.nbd.2026.107603_bb0410","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.3390\/ijms23094718","article-title":"MicroRNA alteration, application as biomarkers, and therapeutic approaches in neurodegenerative diseases","volume":"23","author":"Nguyen","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"17\u201318","key":"10.1016\/j.nbd.2026.107603_bb0415","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1101\/gad.339317.120","article-title":"miR760 regulates ATXN1 levels via interaction with its 5\u2032 untranslated region","volume":"34","author":"Nitschke","year":"2020","journal-title":"Genes Dev."},{"issue":"3","key":"10.1016\/j.nbd.2026.107603_bb0420","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1089\/nat.2021.0020","article-title":"miRNA-mediated knockdown of ATXN3 alleviates molecular disease hallmarks in a mouse model for spinocerebellar ataxia type 3","volume":"32","author":"Nobre","year":"2022","journal-title":"Nucleic Acid Ther."},{"issue":"4","key":"10.1016\/j.nbd.2026.107603_bb0425","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/mds.29355","article-title":"Atrophin-1 function and dysfunction in dentatorubral-pallidoluysian atrophy","volume":"38","author":"Nowak","year":"2023","journal-title":"Mov. Disord."},{"issue":"53","key":"10.1016\/j.nbd.2026.107603_bb0430","doi-asserted-by":"crossref","first-page":"14341","DOI":"10.1523\/JNEUROSCI.2390-08.2008","article-title":"The bifunctional microRNA miR-9\/miR-9* regulates REST and CoREST and is downregulated in Huntington\u2019s disease","volume":"28","author":"Packer","year":"2008","journal-title":"J. Neurosci."},{"issue":"9","key":"10.1016\/j.nbd.2026.107603_bb0435","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.3390\/biom10091269","article-title":"Noncoding RNAs and midbrain DA neurons: novel molecular mechanisms and therapeutic targets in health and disease","volume":"10","author":"Pascale","year":"2020","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.nbd.2026.107603_bb0440","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s12311-018-0917-6","article-title":"Targeting the CACNA1A IRES as a treatment for spinocerebellar ataxia type 6","volume":"17","author":"Pastor","year":"2018","journal-title":"Cerebellum"},{"issue":"7","key":"10.1016\/j.nbd.2026.107603_bb0445","doi-asserted-by":"crossref","DOI":"10.3390\/cells9071698","article-title":"Current status of microRNA-based therapeutic approaches in neurodegenerative disorders","volume":"9","author":"Paul","year":"2020","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.nbd.2026.107603_bb0450","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000200144","article-title":"Cerebellar micro-RNA profile in a mouse model of spinocerebellar ataxia type 2","volume":"10","author":"Paul","year":"2024","journal-title":"Neurol. Genet."},{"key":"10.1016\/j.nbd.2026.107603_bb0455","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.mce.2017.07.005","article-title":"From gene to therapy in spinal and bulbar muscular atrophy: are we there yet?","volume":"465","author":"Pennuto","year":"2018","journal-title":"Mol. Cell. Endocrinol."},{"issue":"12","key":"10.1016\/j.nbd.2026.107603_bb0460","doi-asserted-by":"crossref","first-page":"2316.e17","DOI":"10.1016\/j.neurobiolaging.2010.03.014","article-title":"Genome-wide analysis of miRNA expression reveals a potential role for miR-144 in brain aging and spinocerebellar ataxia pathogenesis","volume":"32","author":"Persengiev","year":"2011","journal-title":"Neurobiol. Aging"},{"issue":"6","key":"10.1016\/j.nbd.2026.107603_bb0465","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1089\/hum.2017.199","article-title":"Artificial miRNAs reduce human mutant huntingtin throughout the striatum in a transgenic sheep model of Huntington\u2019s disease","volume":"29","author":"Pfister","year":"2018","journal-title":"Hum. Gene Ther."},{"issue":"16","key":"10.1016\/j.nbd.2026.107603_bb0470","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1093\/hmg\/ddx191","article-title":"Gene co-expression network analysis for identifying modules and functionally enriched pathways in SCA2","volume":"26","author":"Pflieger","year":"2017","journal-title":"Hum. Mol. Genet."},{"issue":"6","key":"10.1016\/j.nbd.2026.107603_bb0475","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41582-023-00809-y","article-title":"Single-cell and spatial transcriptomics: deciphering brain complexity in health and disease","volume":"19","author":"Piwecka","year":"2023","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.nbd.2026.107603_bb0480","doi-asserted-by":"crossref","DOI":"10.1172\/JCI134565","article-title":"Deubiquitinase USP7 contributes to the pathogenicity of spinal and bulbar muscular atrophy","volume":"131","author":"Pluciennik","year":"2021","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.nbd.2026.107603_bb0485","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/mt.2016.13","article-title":"MiR-298 counteracts mutant androgen receptor toxicity in spinal and bulbar muscular atrophy","volume":"24","author":"Pourshafie","year":"2016","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.nbd.2026.107603_bb0490","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095362","article-title":"RNA interference-based therapy for spinocerebellar ataxia type 7 retinal degeneration","volume":"9","author":"Ramachandran","year":"2014","journal-title":"PloS One"},{"issue":"9","key":"10.1016\/j.nbd.2026.107603_bb0495","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1038\/mt.2014.108","article-title":"Nonallele specific silencing of ataxin-7 improves disease phenotypes in a mouse model of SCA7","volume":"22","author":"Ramachandran","year":"2014","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.nbd.2026.107603_bb0500","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1212\/WNL.0000000000004844","article-title":"MicroRNAs in CSF as prodromal biomarkers for Huntington disease in the PREDICT-HD study","volume":"90","author":"Reed","year":"2018","journal-title":"Neurology"},{"issue":"6772","key":"10.1016\/j.nbd.2026.107603_bb0505","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/35002607","article-title":"The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans","volume":"403","author":"Reinhart","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2026.107603_bb0510","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.mcn.2017.12.009","article-title":"Perturbations in the p53\/miR-34a\/SIRT1 pathway in the R6\/2 Huntington\u2019s disease model","volume":"88","author":"Reynolds","year":"2018","journal-title":"Mol. Cell. Neurosci."},{"issue":"12","key":"10.1016\/j.nbd.2026.107603_bb0515","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.tig.2025.06.005","article-title":"Spatially resolved microRNA expression in tissues: technologies, challenges, and opportunities","volume":"41","author":"Robles-Remacho","year":"2025","journal-title":"Trends Genet."},{"issue":"2","key":"10.1016\/j.nbd.2026.107603_bb0520","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3233\/JHD-200002","article-title":"Huntington\u2019s disease clinical trials corner: April 2020","volume":"9","author":"Rodrigues","year":"2020","journal-title":"J. Huntingtons Dis."},{"key":"10.1016\/j.nbd.2026.107603_bb0525","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.nbd.2013.01.019","article-title":"Altered purkinje cell miRNA expression and SCA1 pathogenesis","volume":"54","author":"Rodriguez-Lebron","year":"2013","journal-title":"Neurobiol. Dis."},{"issue":"6","key":"10.1016\/j.nbd.2026.107603_bb0530","doi-asserted-by":"crossref","first-page":"891","DOI":"10.4161\/rna.19876","article-title":"Regulation of BACE1 by miR-29a\/b in a cellular model of spinocerebellar ataxia 17","volume":"9","author":"Roshan","year":"2012","journal-title":"RNA Biol."},{"issue":"1","key":"10.1016\/j.nbd.2026.107603_bb0535","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12974-017-0925-3","article-title":"microRNA dysregulation in polyglutamine toxicity of TATA-box binding protein is mediated through STAT1 in mouse neuronal cells","volume":"14","author":"Roshan","year":"2017","journal-title":"J. Neuroinflammation"},{"issue":"3","key":"10.1016\/j.nbd.2026.107603_bb0540","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/cge.13978","article-title":"Spinocerebellar ataxia type 2 from an evolutionary perspective: systematic review and meta-analysis","volume":"100","author":"Sena","year":"2021","journal-title":"Clin. Genet."},{"issue":"12","key":"10.1016\/j.nbd.2026.107603_bb0545","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/s41576-023-00611-y","article-title":"microRNAs in action: biogenesis, function and regulation","volume":"24","author":"Shang","year":"2023","journal-title":"Nat. Rev. Genet."},{"issue":"2","key":"10.1016\/j.nbd.2026.107603_bb0550","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/00207454.2013.827679","article-title":"MicroRNA profiling in the serums of SCA3\/MJD patients","volume":"124","author":"Shi","year":"2014","journal-title":"Int. J. Neurosci."},{"issue":"12","key":"10.1016\/j.nbd.2026.107603_bb0555","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/brain\/awae266","article-title":"Exon 1-targeting miRNA reduces the pathogenic exon 1 HTT protein in Huntington\u2019s disease models","volume":"147","author":"Sogorb-Gonzalez","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.nbd.2026.107603_bb0560","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.omtm.2019.03.002","article-title":"AAV5-miHTT gene therapy demonstrates sustained huntingtin lowering and functional improvement in Huntington disease mouse models","volume":"13","author":"Spronck","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"2","key":"10.1016\/j.nbd.2026.107603_bb0565","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00415-018-9076-4","article-title":"Spinocerebellar ataxia: an update","volume":"266","author":"Sullivan","year":"2019","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.nbd.2026.107603_bb0570","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.neuron.2019.01.039","article-title":"Huntingtin lowering strategies for disease modification in Huntington\u2019s disease","volume":"101","author":"Tabrizi","year":"2019","journal-title":"Neuron"},{"issue":"10","key":"10.1016\/j.nbd.2026.107603_bb0575","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41582-020-0389-4","article-title":"Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities","volume":"16","author":"Tabrizi","year":"2020","journal-title":"Nat. Rev. Neurol."},{"issue":"11","key":"10.1016\/j.nbd.2026.107603_bb0580","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/nsmb.2902","article-title":"Cross-talking noncoding RNAs contribute to cell-specific neurodegeneration in SCA7","volume":"21","author":"Tan","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.nbd.2026.107603_bb0585","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.755254","article-title":"MicroRNA-409-3p targeting at ATXN3 reduces the apoptosis of dopamine neurons based on the profile of miRNAs in the cerebrospinal fluid of early Parkinson\u2018s disease","volume":"9","author":"Tan","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.nbd.2026.107603_bb0590","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s10020-023-00695-6","article-title":"Therapeutic effects of engineered exosome-based miR-25 and miR-181a treatment in spinocerebellar ataxia type 3 mice by silencing ATXN3","volume":"29","author":"Tang","year":"2023","journal-title":"Mol. Med."},{"issue":"6","key":"10.1016\/j.nbd.2026.107603_bb0595","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1093\/brain\/awac458","article-title":"AAV5-miHTT-mediated huntingtin lowering improves brain health in a Huntington\u2019s disease mouse model","volume":"146","author":"Thomson","year":"2023","journal-title":"Brain"},{"issue":"7","key":"10.1016\/j.nbd.2026.107603_bb0600","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25073845","article-title":"Huntington\u2019s disease: complex pathogenesis and therapeutic strategies","volume":"25","author":"Tong","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"588","key":"10.1016\/j.nbd.2026.107603_bb0605","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb8920","article-title":"Widespread and sustained target engagement in Huntington\u2019s disease minipigs upon intrastriatal microRNA-based gene therapy","volume":"13","author":"Vall\u00e8s","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"12","key":"10.1016\/j.nbd.2026.107603_bb0610","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1002\/mds.28819","article-title":"Gene therapy for polyglutamine spinocerebellar ataxias: advances, challenges, and perspectives","volume":"36","author":"V\u00e1zquez-Mojena","year":"2021","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.nbd.2026.107603_bb0615","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1523\/JNEUROSCI.5065-07.2008","article-title":"The expression of microRNA miR-107 decreases early in Alzheimer\u2019s disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1","volume":"28","author":"Wang","year":"2008","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.nbd.2026.107603_bb0620","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s12311-022-01431-2","article-title":"The transcription factor, \u03b11ACT, acts through a microRNA network to regulate neurogenesis and cell death during neonatal cerebellar development","volume":"22","author":"Wei","year":"2023","journal-title":"Cerebellum"},{"issue":"4","key":"10.1016\/j.nbd.2026.107603_bb0625","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.3390\/ijms24043443","article-title":"The impact of dysregulated microRNA biogenesis machinery and microRNA sorting on neurodegenerative diseases","volume":"24","author":"Weng","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.nbd.2026.107603_bb0630","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/0092-8674(93)90530-4","article-title":"Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. Elegans","volume":"75","author":"Wightman","year":"1993","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.nbd.2026.107603_bb0635","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3233\/JAD-150619","article-title":"Circulating microRNAs as biomarkers of Alzheimer\u2019s disease: a systematic review","volume":"49","author":"Wu","year":"2016","journal-title":"J. Alzheimer\u2019s Dis"},{"issue":"1","key":"10.1016\/j.nbd.2026.107603_bb0640","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12929-020-00636-z","article-title":"Functional roles and networks of non-coding RNAs in the pathogenesis of neurodegenerative diseases","volume":"27","author":"Wu","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.nbd.2026.107603_bb0645","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3389\/fnmol.2018.00153","article-title":"Transcriptional dysregulation and post-translational modifications in polyglutamine diseases: from pathogenesis to potential therapeutic strategies","volume":"11","author":"Xiang","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.nbd.2026.107603_bb0650","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.neuroscience.2020.04.004","article-title":"Global knockdown of retinoid-related orphan receptor \u03b1 in mature purkinje cells reveals aberrant cerebellar phenotypes of spinocerebellar ataxia","volume":"462","author":"Yasui","year":"2021","journal-title":"Neuroscience"},{"issue":"11","key":"10.1016\/j.nbd.2026.107603_bb0655","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202601357RR","article-title":"Engineered exosomes deliver miR-370 inhibitor to regulate DNAJB1 and synergize with miR-25 in improving SCA3 mice behavior and neuropathology","volume":"40","author":"Zhang","year":"2026","journal-title":"FASEB J."},{"issue":"15","key":"10.1016\/j.nbd.2026.107603_bb0660","doi-asserted-by":"crossref","first-page":"11942","DOI":"10.3390\/ijms241511942","article-title":"Dysregulated miRNA and mRNA expression affect overlapping pathways in a Huntington\u2019s disease model","volume":"24","author":"Zsindely","year":"2023","journal-title":"Int. J. Mol. Sci."}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996126003487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996126003487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:46:41Z","timestamp":1791082001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996126003487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":132,"alternative-id":["S0969996126003487"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2026.107603","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MicroRNAs in polyglutamine diseases: Mechanistic insights, circulating biomarkers, and emerging microRNA-based therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2026.107603","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107603"}}